Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Dollar Strengthens as U.S.-Iran Peace Talks Send Mixed Signals 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
